Piclozotan

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Piclozotan
Accession Number
DB12361
Type
Small Molecule
Groups
Investigational
Description

Piclozotan has been investigated for the treatment of Parkinson's Disease.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
FQE44HS7AH
CAS number
182415-09-4
Weight
Average: 409.91
Monoisotopic: 409.1557047
Chemical Formula
C23H24ClN3O2
InChI Key
URMTUEWUIGOJBW-UHFFFAOYSA-N
InChI
InChI=1S/C23H24ClN3O2/c24-22-17-29-21-9-2-1-7-19(21)23(28)27(22)14-6-5-13-26-15-10-18(11-16-26)20-8-3-4-12-25-20/h1-4,7-10,12,17H,5-6,11,13-16H2
IUPAC Name
3-chloro-4-(4-{1',2',3',6'-tetrahydro-[2,4'-bipyridine]-1'-yl}butyl)-4,5-dihydro-1,4-benzoxazepin-5-one
SMILES
ClC1=COC2=CC=CC=C2C(=O)N1CCCCN1CCC(=CC1)C1=CC=CC=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Piclozotan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Piclozotan.Approved, Investigational, Vet Approved
AmphetamineThe metabolism of Piclozotan can be decreased when combined with Amphetamine.Approved, Illicit, Investigational
BenmoxinThe metabolism of Piclozotan can be decreased when combined with Benmoxin.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Piclozotan.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Piclozotan.Approved
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Piclozotan.Approved, Investigational
BrofaromineThe metabolism of Piclozotan can be decreased when combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the vasoconstricting activities of Piclozotan.Approved, Investigational
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Piclozotan.Approved
CabergolineCabergoline may increase the vasoconstricting activities of Piclozotan.Approved
CaroxazoneThe metabolism of Piclozotan can be decreased when combined with Caroxazone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Piclozotan.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Piclozotan.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Piclozotan.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Piclozotan.Approved, Illicit
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Piclozotan.Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Piclozotan.Approved
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Piclozotan.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Piclozotan.Approved
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Piclozotan.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Piclozotan.Approved, Vet Approved
DroxidopaPiclozotan may increase the hypertensive activities of Droxidopa.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Piclozotan.Approved, Investigational
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Piclozotan.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Piclozotan.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Piclozotan.Approved
EthanolPiclozotan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Piclozotan.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Piclozotan.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Piclozotan.Approved, Illicit, Investigational, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Piclozotan.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Piclozotan.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Piclozotan.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Piclozotan is combined with Fluvoxamine.Approved, Investigational
FurazolidoneThe metabolism of Piclozotan can be decreased when combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Piclozotan.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Piclozotan.Approved, Investigational
HarmalineThe metabolism of Piclozotan can be decreased when combined with Harmaline.Experimental
HydracarbazineThe metabolism of Piclozotan can be decreased when combined with Hydracarbazine.Experimental
HydrocodonePiclozotan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Piclozotan.Approved
IproclozideThe metabolism of Piclozotan can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Piclozotan can be decreased when combined with Iproniazid.Withdrawn
IsocarboxazidThe metabolism of Piclozotan can be decreased when combined with Isocarboxazid.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Piclozotan.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Piclozotan.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Piclozotan.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Piclozotan.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Piclozotan.Approved
Magnesium sulfateThe therapeutic efficacy of Piclozotan can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Piclozotan.Approved
MebanazineThe metabolism of Piclozotan can be decreased when combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Piclozotan.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Piclozotan.Approved
Methylene blueThe metabolism of Piclozotan can be decreased when combined with Methylene blue.Approved, Investigational
MethylergometrineMethylergometrine may increase the vasoconstricting activities of Piclozotan.Approved
MinaprineThe metabolism of Piclozotan can be decreased when combined with Minaprine.Approved
MoclobemideThe metabolism of Piclozotan can be decreased when combined with Moclobemide.Approved, Investigational
NialamideThe metabolism of Piclozotan can be decreased when combined with Nialamide.Withdrawn
OctamoxinThe metabolism of Piclozotan can be decreased when combined with Octamoxin.Withdrawn
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Piclozotan.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Piclozotan.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Piclozotan.Approved, Investigational, Vet Approved
PargylineThe metabolism of Piclozotan can be decreased when combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Piclozotan.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Piclozotan is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Piclozotan.Experimental
PhenelzineThe metabolism of Piclozotan can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Piclozotan can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Piclozotan.Approved, Investigational
PhenoxypropazineThe metabolism of Piclozotan can be decreased when combined with Phenoxypropazine.Withdrawn
PirlindoleThe metabolism of Piclozotan can be decreased when combined with Pirlindole.Approved
PivhydrazineThe metabolism of Piclozotan can be decreased when combined with Pivhydrazine.Withdrawn
PramipexolePiclozotan may increase the sedative activities of Pramipexole.Approved, Investigational
PregabalinThe therapeutic efficacy of Piclozotan can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProcaineThe metabolism of Piclozotan can be decreased when combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe metabolism of Piclozotan can be decreased when combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Piclozotan.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Piclozotan.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Piclozotan is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Piclozotan.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Piclozotan.Approved
RasagilineThe metabolism of Piclozotan can be decreased when combined with Rasagiline.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Piclozotan.Approved
SafrazineThe metabolism of Piclozotan can be decreased when combined with Safrazine.Withdrawn
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Piclozotan.Approved, Investigational
SelegilineThe metabolism of Piclozotan can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Piclozotan.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Piclozotan.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Piclozotan.Investigational
ToloxatoneThe metabolism of Piclozotan can be decreased when combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Piclozotan.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Piclozotan.Approved, Investigational
TranylcypromineThe metabolism of Piclozotan can be decreased when combined with Tranylcypromine.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Piclozotan.Approved
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Piclozotan.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Piclozotan.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Piclozotan.Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Piclozotan.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Piclozotan.Approved, Investigational
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Piclozotan.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
9801640
PubChem Substance
347828614
ChemSpider
7977402
BindingDB
50097342
ChEMBL
CHEMBL345237
Wikipedia
Piclozotan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentParkinson's Disease (PD)1
2TerminatedTreatmentStrokes1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0685 mg/mLALOGPS
logP4.3ALOGPS
logP3.75ChemAxon
logS-3.8ALOGPS
pKa (Strongest Basic)8.48ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area45.67 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity126.13 m3·mol-1ChemAxon
Polarizability45.08 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoxazepines. These are organic compounds containing a benzene fused to an oxazepine ring (a seven-membered ring with four carbon atoms, one oxygen atom, and a nitrogen atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxazepines
Sub Class
Not Available
Direct Parent
Benzoxazepines
Alternative Parents
Hydropyridines / Benzenoids / Tertiary carboxylic acid amides / Heteroaromatic compounds / Trialkylamines / Lactams / Amino acids and derivatives / Vinyl chlorides / Oxacyclic compounds / Chloroalkenes
show 5 more
Substituents
Benzoxazepine / Hydropyridine / Pyridine / Benzenoid / Tertiary carboxylic acid amide / Heteroaromatic compound / Amino acid or derivatives / Carboxamide group / Lactam / Tertiary amine
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 16:05 / Updated on August 02, 2018 06:37